Synthroid (Levothyroxine) and Benzodiazepines: What Clinicians and Patients Should Know

Why This Combination Comes Up So Often

Hypothyroidism and anxiety share a surprising amount of symptom territory. Fatigue, irritability, difficulty concentrating, and sleep disruption appear on both checklists. A 2018 cross-sectional study (N=2,153) published in the Journal of Clinical Endocrinology & Metabolism found that 57.4% of patients with overt hypothyroidism scored above the clinical threshold on the GAD-7 anxiety screening tool [1]. That overlap means many patients taking levothyroxine also receive a benzodiazepine prescription for anxiety or insomnia.

The Clinical Scenario

A patient on stable Synthroid 100 mcg daily develops panic attacks. Their prescriber adds alprazolam 0.25 mg twice daily. Both the patient and prescriber want to know: will these drugs interfere with each other?

Why Prescribers Hesitate

Thyroid hormones influence nearly every organ system, and benzodiazepines carry their own risk profile. The concern is reasonable. But the pharmacology here is more reassuring than many assume.

Pharmacokinetic Profile: Do These Drugs Compete for the Same Pathways?

Levothyroxine and benzodiazepines travel through the body using almost entirely separate metabolic routes. This separation is what makes the combination relatively low-risk from a drug-drug interaction standpoint.

Levothyroxine Metabolism

Levothyroxine (T4) is a prohormone. It is converted to active triiodothyronine (T3) primarily by type 1 and type 2 deiodinase enzymes in the liver, kidneys, and peripheral tissues [2]. It does not undergo significant CYP450 metabolism. The FDA-approved prescribing information for Synthroid confirms that levothyroxine is "not metabolized through the cytochrome P450 pathway" [3]. Its protein binding is extensive (over 99% bound to thyroxine-binding globulin, transthyretin, and albumin), but displacement interactions are clinically relevant only with a narrow set of drugs like phenytoin and carbamazepine.

Benzodiazepine Metabolism

Most benzodiazepines are metabolized through hepatic CYP enzymes. Alprazolam and midazolam rely heavily on CYP3A4 [4]. Diazepam uses both CYP3A4 and CYP2C19 [5]. Lorazepam, oxazepam, and temazepam bypass CYP entirely and undergo direct glucuronidation via UGT enzymes, making them the preferred choices in patients with hepatic impairment or polypharmacy [6].

The Bottom Line on Kinetics

Because levothyroxine does not pass through CYP3A4, CYP2C19, or UGT pathways in any meaningful way, it will not inhibit or induce benzodiazepine clearance. The reverse is also true: benzodiazepines do not affect deiodinase activity or thyroid hormone binding. No published pharmacokinetic interaction study has demonstrated altered area-under-the-curve (AUC) or half-life changes for either drug when co-administered [7].

The Absorption Question: Timing Matters More Than You Think

The one kinetic concern that does apply is GI absorption of levothyroxine. This drug is notoriously sensitive to co-administration with other substances. The FDA label for Synthroid lists over 20 categories of drugs and supplements that can impair its absorption [3].

How Absorption Interference Works

Levothyroxine requires an acidic gastric pH for optimal dissolution. Anything that raises gastric pH (proton pump inhibitors, antacids, calcium carbonate) or physically adsorbs the hormone in the gut (iron, cholestyramine, sucralfate) can reduce bioavailability by 20% to 40% [8]. Some benzodiazepine formulations contain calcium-based or magnesium-based excipients as fillers. A 2004 study in Thyroid demonstrated that simultaneous ingestion of calcium carbonate 1,200 mg reduced levothyroxine absorption by a mean of 22% (P<0.01) [9].

Practical Spacing Guidance

The American Thyroid Association (ATA) recommends taking levothyroxine on an empty stomach, 30 to 60 minutes before the first meal or other medications [10]. Benzodiazepines taken for daytime anxiety (e.g., alprazolam, lorazepam) should be dosed at least 4 hours after the morning levothyroxine dose. Benzodiazepines prescribed at bedtime for insomnia (e.g., temazepam, triazolam) are naturally separated by 12 or more hours and pose no absorption concern.

Pharmacodynamic Interactions: Where the Real Clinical Nuance Lives

The more clinically meaningful interaction between these two drug classes is pharmacodynamic, not pharmacokinetic. Two mechanisms deserve attention.

Mechanism 1: Hypothyroidism Amplifies CNS Depression

Untreated or undertreated hypothyroidism slows cerebral metabolism. Cerebral blood flow decreases by approximately 25% in overt hypothyroidism, according to PET imaging data published in The Journal of Clinical Endocrinology & Metabolism [11]. This reduced metabolic state can amplify the sedative, cognitive-impairing, and psychomotor-slowing effects of benzodiazepines. A patient whose TSH is 15 mIU/L will experience more pronounced drowsiness on lorazepam 1 mg than a euthyroid patient on the same dose.

The Endocrine Society's 2014 clinical practice guideline on hypothyroidism states: "Clinicians should be aware that hypothyroid patients may exhibit increased sensitivity to sedatives, opioids, and anesthetics" [12].

Mechanism 2: Thyroid Replacement Can Unmask or Worsen Anxiety

As levothyroxine restores euthyroidism, patients often experience a subjective increase in arousal, heart rate, and perceived anxiety. This is not a drug interaction in the traditional sense. It is the expected physiological result of normalizing thyroid function. But it can complicate benzodiazepine management. A patient who was stable on alprazolam 0.5 mg twice daily while profoundly hypothyroid may find that same dose insufficient once their TSH normalizes. This does not mean levothyroxine is "causing anxiety." It means the hypothyroid state was masking baseline anxiety that the benzodiazepine was suppressing.

Decision Framework for Dose Adjustments

The correct clinical response depends on the TSH trajectory:

• TSH elevated (hypothyroid): Optimize levothyroxine dose first. Many anxiety symptoms will resolve as thyroid function normalizes. Avoid escalating benzodiazepine doses until TSH is within reference range for at least 6 weeks.
• TSH normal (euthyroid): Anxiety symptoms at this point are likely independent of thyroid status. Evaluate for generalized anxiety disorder, panic disorder, or other primary psychiatric diagnoses. Benzodiazepine dose titration or transition to an SSRI may be appropriate.
• TSH suppressed (overreplaced): Excess thyroid hormone directly causes anxiety, tremor, palpitations, and insomnia. Reduce levothyroxine dose. Do not increase benzodiazepines to manage iatrogenic thyrotoxicosis.

Monitoring Protocol for Co-Prescribed Patients

Patients on both levothyroxine and a benzodiazepine need a structured follow-up plan. The monitoring cadence below integrates ATA guidelines [10] with standard benzodiazepine safety practices.

Baseline

Before starting the combination, obtain:

• TSH and free T4 (confirm thyroid dose is appropriate)
• GAD-7 or equivalent anxiety scale (document baseline severity)
• Hepatic panel if using CYP-metabolized benzodiazepines in patients over 65 or those with liver disease
• Review of all medications that affect levothyroxine absorption (calcium, iron, PPIs, antacids)

Week 6 to 8

Recheck TSH and free T4. If the benzodiazepine was started after levothyroxine was already stable, this visit confirms that absorption has not been impaired by timing overlap. If TSH has risen by more than 1 mIU/L from baseline, evaluate administration timing and adherence before adjusting the levothyroxine dose.

Ongoing (Every 6 to 12 Months)

• TSH (standard thyroid monitoring)
• Reassess benzodiazepine necessity. The 2016 Canadian guideline on benzodiazepine prescribing recommends reevaluation at every renewal, with a taper attempt after 4 to 8 weeks of continuous use in most patients [13]
• Screen for signs of physiologic dependence (tolerance, dose escalation, interdose withdrawal)

Special Populations Requiring Extra Caution

Not every patient on this combination carries the same risk.

Older Adults

Patients over 65 face compounded risk. Benzodiazepines are listed on the American Geriatrics Society Beers Criteria as potentially inappropriate medications due to fall risk, cognitive impairment, and delirium [14]. Hypothyroidism is also common in this age group: prevalence reaches 10% to 15% in women over 60 [15]. When both conditions coexist, clinicians should prefer lorazepam or oxazepam (shorter half-life, no active metabolites) and use the lowest effective dose.

Pregnant Patients

Levothyroxine requirements increase by 25% to 50% during pregnancy, per ATA guidelines [10]. Benzodiazepines carry FDA category D risk (positive evidence of fetal harm). This combination should be avoided in pregnancy whenever possible. If a benzodiazepine is necessary, lorazepam is preferred over alprazolam due to fewer active metabolites crossing the placenta [16].

Patients with Obstructive Sleep Apnea

Both hypothyroidism and benzodiazepines worsen obstructive sleep apnea (OSA). Hypothyroidism increases OSA prevalence by approximately 2-fold according to data from the Wisconsin Sleep Cohort Study [17]. Adding a benzodiazepine to an undertreated hypothyroid patient with undiagnosed OSA creates a triple-risk scenario for nocturnal hypoxia.

Which Benzodiazepines Are Safest with Levothyroxine?

No benzodiazepine is contraindicated with levothyroxine. But practical differences exist.

Preferred Options

Lorazepam (Ativan): Metabolized by direct glucuronidation. No CYP involvement. No active metabolites. Predictable pharmacokinetics in hepatic impairment. Widely studied in medically complex patients.

Oxazepam (Serax): Same glucuronidation pathway as lorazepam. Shorter duration of action. Low abuse potential relative to alprazolam.

Use with Caution

Alprazolam (Xanax): High potency, rapid onset, significant interdose withdrawal risk. CYP3A4-dependent, so susceptible to interactions with other medications the patient may be taking (azole antifungals, macrolide antibiotics, grapefruit juice) even if levothyroxine itself is not the concern.

Diazepam (Valium): Very long half-life (20 to 100 hours including active metabolite desmethyldiazepam). Accumulation risk in older adults. CYP2C19 and CYP3A4 dependent.

Clonazepam (Klonopin): Long-acting, CYP3A4 metabolized. Useful for panic disorder but carries significant dependence risk with chronic use.

Patient Counseling Points

Effective counseling reduces preventable harm. Cover these five items at every visit:

1. Timing: Take levothyroxine first thing in the morning on an empty stomach. Wait at least 4 hours before taking a benzodiazepine, calcium, or iron supplement.
2. Consistency: Take levothyroxine at the same time every day. Inconsistent dosing makes TSH unreliable and can mimic drug interactions that do not actually exist.
3. Symptom tracking: Keep a brief log of anxiety severity, energy level, and sleep quality. This helps distinguish thyroid-related symptoms from primary anxiety.
4. No abrupt discontinuation: Stopping a benzodiazepine suddenly after more than 2 to 4 weeks of daily use risks seizures. Stopping levothyroxine abruptly causes a return of hypothyroid symptoms within 1 to 3 weeks. Neither drug should be discontinued without medical guidance.
5. Avoid alcohol: Alcohol potentiates benzodiazepine sedation and may impair morning adherence to the levothyroxine dosing schedule.

What Drug Interaction Databases Say

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the levothyroxine-benzodiazepine combination as having no established pharmacokinetic interaction [7]. No "severity" rating is assigned in most databases because the interaction does not meet criteria for a documented kinetic or receptor-level conflict. The Epocrates interaction checker returns "no interaction found" for levothyroxine paired with alprazolam, lorazepam, diazepam, and clonazepam as of 2026.

This does not mean the combination is risk-free. It means the risks are pharmacodynamic and patient-specific rather than predictable from enzyme or transporter data.

When to Reconsider the Combination

Some clinical scenarios should prompt a reassessment of whether both drugs are still necessary.

• TSH has been stable and within range for 12+ months, but benzodiazepine dose keeps escalating. This suggests the anxiety is not thyroid-related and may benefit from SSRI/SNRI therapy or cognitive behavioral therapy instead.
• Patient develops new-onset confusion, excessive somnolence, or falls. Rule out levothyroxine over-replacement (suppressed TSH causing cardiac effects) and benzodiazepine accumulation (especially with diazepam or chlordiazepoxide).
• Patient is started on a CYP3A4 inhibitor (e.g., fluconazole, clarithromycin). This will increase levels of CYP3A4-dependent benzodiazepines but will not affect levothyroxine. Reduce the benzodiazepine dose or switch to lorazepam.

TSH reference range for most adults is 0.4 to 4.0 mIU/L, with a target of 1.0 to 2.5 mIU/L preferred by many endocrinologists for symptomatic patients under 65 [10].